{"id":"W2945103009","doi":"10.1186/s12885-019-5507-6","title":"Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials","year":2019,"lang":"en","type":"review","venue":"BMC Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Medicine; Anaplastic lymphoma kinase; Erlotinib; Oncology; Internal medicine; Atezolizumab; Lung cancer; Epidermal growth factor receptor; Pembrolizumab; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01343181,0.002098838,0.01929789,0.007266911,0.0006012737,0.003009144,0.00156932,0.002276886,0.004846189],"category_scores_gemma":[0.03884688,0.001038801,0.01728656,0.006449737,0.001158067,0.002008135,0.001302659,0.001577699,0.0003834619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003821941,"about_ca_system_score_gemma":0.005476973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003468354,"about_ca_topic_score_gemma":0.009164117,"domain_scores_codex":[0.9873832,0.00545109,0.004503705,0.001047289,0.001332555,0.0002821968],"domain_scores_gemma":[0.9704843,0.02046951,0.006173657,0.000517952,0.002051939,0.0003027753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001921211,0.00002316113,0.0007759057,0.8949869,0.09291776,0.00008005657,0.00007956062,0.0001087455,0.0002216977,0.0001348879,0.000400593,0.008349572],"study_design_scores_gemma":[0.003628279,0.0009438209,0.004416333,0.2456339,0.7384599,0.0002450629,0.0001647655,0.0001956286,0.0004172113,0.0005308383,0.005308935,0.00005536512],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006734961,0.9887318,0.0004517355,0.0002198133,0.0001824484,0.002063419,0.001106736,0.00002596834,0.000483216],"genre_scores_gemma":[0.1641325,0.8216816,0.003240475,0.001275201,0.0002619414,0.007274524,0.001490373,0.00003360924,0.0006097521],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01929789,"threshold_uncertainty_score":0.07103503,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1126703746187524,"score_gpt":0.4312807990143271,"score_spread":0.3186104243955747,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}